Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cornerstone Launches Bethkis | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Cornerstone Launches Bethkis

Nebulized treatment for CF patients with Pseudomonas aeruginosa

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Cornerstone Therapeutics has launched of Bethkis (Tobramycin Inhalation Solution), a nebulized therapy indicated for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.

Bethkis contains 300 mg of tobramycin, the most widely used aerosolized antibiotic in patients with CF. Bethkis’ concentrated formulation delivers the same amount of antibiotic as other available nebulized tobramycin products (300 mg) in 4 mLs, allowing nebulization in approximately 15 minutes via the PARI LC® PLUS.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics